Recruiting

CGM

Sponsor:

UCLA

Code:

NCT04783441

Conditions

Kidney Transplant; Complications

Diabetes Mellitus, Type 2

Insulin Dependent Diabetes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dexcom G6

Dexcom G6 blinded sensor

Study Details

Brief summary:

The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.

Conditions

Kidney Transplant; Complications

Diabetes Mellitus, Type 2

Insulin Dependent Diabetes

Study ID

NCT04783441

Start date

Jun 29, 2021

Status verified date

Jan, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age 18 or above
2. Received a kidney transplant within the past year with functioning kidney (eGFR > 30 mL/min
3. Person with Type 2 Diabetes and on insulin
4. Access to home wi-fi connection

Exclusion Criteria:

1. Person with Type 1 Diabetes
2. Patients taking hydroxyurea
3. Patient unable to wear the Dexcom G6 device at all times for any reason
4. Must be able to test blood glucose with meter 4x a day when on blinded CGM.
5. Presence of clinically significant visual or cognitive impairment
6. Illiterate
7. Prisoners
8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding
9. Presence of clinically unstable cardiovascular disease
10. Active malignancy treatment

Study Design

Enrollment

80 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

active comparator: Continuous glucose monitoring (CGM)

Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.

placebo comparator: Self monitoring of blood glucose (fingersticks)

The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.

Interventions

Dexcom G6

access to continuous glucose monitoring in the Dexcom G6 arm 24/7

Dexcom G6 blinded sensor

retrospective access to continuous glucose profile after 10 days of wear

Primary outcome measure

  • Time in Range (70-180 mg/dl) [ Time Frame: 70 days ]

Central Contacts and Locations

Central contacts

Dahlia Zuidema, PharmD

916-734-4009dmzuidema@ucdavis.edu

Clinical Research Coordinators

916-734-4009HS-TransplantCenterResearch@ucdavis.edu

Locations

UC Davis Health

Recruiting

Sacramento, California, United States, 95817

Contacts

Dahlia Zuidema, PharmD

916-734-4009dmzuidema@ucdavis.edu

More Information

Sponsor

University of California, Davis

Last update posted

Jan 29, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of California, Davis on 2026-01-29.